Negligible nuclear FOXP3 expression in breast cancer epithelial cells compared with FOXP3-positive T cells

Clinical Breast Cancer

Volumn 13, Issue 4, 2013, Pages 264-270

  Droeser, Raoul A ^a,b   Obermann, Ellen C ^a   Wolf, Anna Maria ^c,d   Wallner, Stephanie ^d   Wolf, Dominik ^c,d   Tzankov, Alexandar ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Breast cancer cell lines; Epithelial tumor cells; Forkhead box protein 3; Immunohistochemistry; Tissue microarray

Indexed keywords

MESSENGER RNA; TRANSCRIPTION FACTOR FOXP3;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER CELL; CANCER GRADING; CANCER SURVIVAL; CELL LINE; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TISSUE MICROARRAY;

EID: 84884686329     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2013.02.009     Document Type: Article

References (35)

1. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003;4:330-6.
2. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature 2007;445:931-5.
3. Feuerer M, Hill JA, Mathis D, et al. Foxp3+ regulatory T cells: differentiation, specification, subphenotypes. Nat Immunol 2009;10:689-95.
4. Josefowicz SZ, Rudensky A. Control of regulatory T cell lineage commitment and maintenance. Immunity 2009;30:616-25.
5. Curiel TJ. Regulatory T cells and treatment of cancer. Curr Opin Immunol 2008;20:241-6.
6. Roncarolo MG, Gregori S. Is FOXP3 a bona fide marker for human regulatory T cells? Eur J Immunol 2008;38:925-7.
7. Siegmund K, Ruckert B, Ouaked N, et al. Unique phenotype of human tonsillar and in vitro-induced FOXP3+CD8+ T cells. J Immunol 2009;182:2124-30.
8. Chen GY, Chen C, Wang L, et al. Cutting edge: broad expression of the FoxP3 locus in epithelial cells: a caution against early interpretation of fatal inflammatory diseases following in vivo depletion of FoxP3-expressing cells. J Immunol 2008;180:5163-6.
9. Martin F, Ladoire S, Mignot G, et al. Human FOXP3 and cancer. Oncogene 2010;29:4121-9.
10. Ladoire S, Arnould L, Mignot G, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 2011;125:65-72.
11. Zuo T, Wang L, Morrison C, et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER2/ErbB2 oncogene. Cell 2007;129:1275-86.
12. Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol 2009;27:1746-52.
13. Ladoire S, Mignot G, Dalban C, et al. FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial. Ann Oncol 2012;2:2552-61.
14. Wolf D, Wolf AM, Tzankov A. Comment on "Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice". J Immunol 2010;184:4051.
15. Wang L, Liu R, Li W, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009;16:336-46.
16. Jung DJ, Jin DH, Hong SW, et al. Foxp3 expression in p53-dependent DNA damage responses. J Biol Chem 2010;285:7995-8002.
17. McInnes N, Sadlon TJ, Brown CY, et al. FOXP3 and FOXP3-regulated micro-RNAs suppress SATB1 in breast cancer cells. Oncogene 2012;31:1045-54.
18. Tzankov A, Went P, Zimpfer A, et al. Tissue microarray technology: principles, pitfalls and perspectives-lessons learned from hematological malignancies. Exp Gerontol 2005;40:737-44.
19. Tzankov A, Meier C, Hirschmann P, et al. Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma. Haematologica 2008;93:193-200.
20. Wolf D, Wolf AM, Rumpold H, et al. The expression of the regulatory T cellspecific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005;11:8326-31.
21. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
22. Droeser R, Zlobec I, Kilic E, et al. Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+ tumor infiltrating lymphocytes in ductal and lobular breast cancers. BMC Cancer 2012;12:134.
23. Ben Shoshan J, Maysel-Auslender S, Mor A, et al. Hypoxiacontrols CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur J Immunol 2008;38:2412-8.
24. Bates GJ, Fox SB, Han C, et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse. J Clin Oncol 2006;24:5373-80.
25. Bohling SD, Allison KH. Immunosuppressive regulatory T cells are associated with aggressive breast cancer phenotypes: a potential therapeutic target. Mod Pathol 2008;21:1527-32.
26. De Kruijf EM, Van Nes JG, Sajet A, et al. The predictive value of HLA class I tumor cell expression and presence of intratumoral Tregs for chemotherapy in patients with early breast cancer. Clin Cancer Res 2010;16:1272-80.
27. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 2005;22:329-41.
28. Salama P, Phillips M, Grieu F, et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009;27:186-92.
29. Frey DM, Droeser RA, Viehl CT, et al. High frequency of tumor-infiltrating FOXP3 (+) regulatory T cells predicts improved survival in mismatch repairproficient colorectal cancer patients. Int J Cancer 2010;126:2635-43.
30. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9.
31. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866-72.
32. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-50.
33. Ebert LM, Tan BS, Browning J, et al. The regulatory T cell-associated transcription factor FoxP3 is expressed by tumor cells. Cancer Res 2008;68:3001-9.
34. Kim J, Lahl K, Hori S, et al. Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol 2009;183:7631-4.
35. Mahmoud SM, Paish EC, Powe DG, et al. An evaluation of the clinical significance of FOXP3 (+) infiltrating cells in human breast cancer. Breast Cancer Res Treat 2011;127:99-108.